To evaluate whether EFR3A was similarly required for KRAS-mutant pancreatic tumor growth, the aforementioned HPAF-II cells, in which the expression of EFR3A, EFR3B, or both genes was verified to be reduced (Fig. 3f), were injected subcutaneously into immunocompromised mice. This evidence concerns the gene EFR3B and pancreatic neoplasm.